Any savvy investor can see the medical cannabis industry is much broader and diverse than the simple sale of cannabis. Retail dispensary sales account for slightly less than 28% of the more than $11B greater cannabis industry. With legalization sweeping the country and a steady change in attitudes, the medical cannabis industry is ripe for disruption and innovation, and that’s just what Med-X, Inc. (“Med-X”) and its experienced team of doctors and scientists have been recognizing over the last year or so.

Rewards based crowdfunding tends to be consumer facing and product focused. But the SEC’s new rules for Reg A+ equity crowdfunding, with its alluring larger investment limit, attracts companies with varied visions from different industries. Companies have launched Reg A+ campaigns for everything from innovative automobiles and advanced airplanes, to video games and pet locators, but is has yet to hit the medical cannabis industry.

Los Angeles based medical cannabis company, Med-X, Inc., aims to make history and change that with the first ever Reg A+ equity crowdfunding campaign in the cannabis industry. Since its inception in 2014, Med-X has been dedicated to fundamentally affecting the cannabis industry at every level.

“Our desire to innovate all-natural solutions will never waiver. Our passion for education will fuel our development. Our mission to cultivate natural medicine will bring lasting change.” – Med-X

Med-X was founded by a team of highly experienced doctors, leaders, investors, and enthusiasts aiming to revolutionize the cannabis lifestyle through education, innovation, and cultivation. The Marijuana Times, Med-X’s educational media division seeks to dispel myths about the industry and cannabis itself, as well as produces the kind of informative content demanded by the community. Med-X is dedicated to producing innovative products for the cultivation of medical cannabis. Med-X’s exclusively licensed product, Nature-Cide All Purpose Insecticide, is an all-natural pesticide that uses essential oils and advanced cultivation technology to safely neutralize plant pests that ruin harvests. As soon as Nature-Cide was registered nationally in the 39 states that require EPA registration, the Agricultural Department of Colorado approved its use for the cultivation of cannabis. CEO Dr. David Toomey runs the research and development of medical cannabis itself, to provide new and exciting medicinal breakthroughs to medical cannabis patients.

This complete approach to the cannabis industry is necessary to effect real change across the country while still producing medical breakthroughs, is Med-X’s primary concern. Med-X is dedicated to patient health first, and second serving its community with the highest quality medicines. “You’re not just investing in a cannabis company, you’re investing in green medicine”, says Dr. David Toomey, an important sentiment shared by the whole company.

Management’s dedication to this cannabis community first weighed heavily on their decision to run an equity crowdfunding campaign. Equity crowdfunding lets Med-X connect with the cannabis community and offer people a rare opportunity to invest in an important equity crowdfunding campaign. For investors, Med-X’s unique approach to the cannabis industry is an intriguing opening into the growing medical cannabis market.

If Med-X is successful in their Reg A+ campaign, they will have positioned themselves well to seize a special opportunity in the medical cannabis industry and get people involved using their combined experience and vision. Their multi-pronged approach will cover every level of cannabis production and patient experience, giving Med-X a unique position of superiority in the budding industry.

Source: https://www.startengine.com/startup/med-x

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of marijuanatimes.org. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.

THIS STORY MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, MED-X, INC., ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO MED-X, INC.’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. MED-X, INC. DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.